Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
NCT Number:
NCT04471844
Phase:
N/A
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Brain and Nervous System
Study Objectives:
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
If you would like to contact a MUSC study team member to learn more information about this study, click
HERE.